With A CAGR Of 8.36%, Rectovaginal Fistula Market Is Projected To Reach USD 2,019 Million By 2030
Rectovaginal Fistula Market Size Was Valued at USD 1,062 Million in 2022, and is Projected to Reach USD 2,019 Million by 2030, Growing at a CAGR of 8.36% From 2023-2030.
The Rectovaginal Fistula Market encompasses the global industry focused on addressing rectovaginal fistulas, which are abnormal connections between the rectum and vagina. This medical condition can result from various factors, including childbirth complications, surgeries, and certain diseases.
The rectovaginal fistula is described in medical terms as an abnormal epithelial line between the rectum and vagina. One of the main causes of the rectovaginal fistula is childbirth. Prolonged labor with necrosis of the part or an obstetric injury with a third or fourth-degree perineal tear could result in the rectovaginal fistula. Infection, breakdown of the repair, or any injury near that region also could result in the rectovaginal fistula.
Key Prominent Players In The Rectovaginal Fistula Market:
Boston Scientific (US),Stryker (US),Ethicon (US),Teleflex (US),Cook Medical (US),Acelity (US),MiMedx (US),American College of Obstetricians and Gynecologists (US),Fistula Foundation (US),AMS (US),C.R. Bard, Inc. (US),Teleflex Medical Incorporated (US),GE Healthcare (US),Medtronic (Ireland),Bard (UK),Shire Regenerative Medicine (UK),Siemens Healthineers (Germany),Philips Healthcare (Netherlands),Esaote (Italy),Fondation Jean-François (France),LABORIE (France),S.I.M.S. (Belgium),Shimadzu (Japan)
Get Access to Sample Pages + Covid-19 impact analysis
https://introspectivemarke...